Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and the Nasdaq gained +2% and touched another new all-time
high. Short-term support for both indices remains at their respective 10-DMA (5,184/16,242) followed by the rising 21-DMA
(5,136/16,117). The distribution day count declined to four and seven, respectively, with another day set to expire on each index after
the close on Monday.

O’Neil Health Care Weekly

XLV has been consolidating for four weeks, pulling back 73bps last week and now narrowly below its 21-DMA ($145.56). Support
below this level is the rising 50-DMA ($143.20). We continue to recommend an equal-weight sector positioning given its RS line
remains in a longer-term downtrend.

Market View

The U.S. market remains in a Confirmed Uptrend. Last week, the S&P 500 fell 0.1%, while the Nasdaq lost 0.7%. The S&P 500 is testing support at its 21-DMA (5,089). The Nasdaq is slightly below its 21-DMA (15,997), leaving its next support 2% below at its 50-DMA (15,618). It has not been below the 50-DMA since early-November 2023. The distribution day count on the indices is elevated at six and nine, respectively. However, three will expire on each index over the next six trading days.

O’Neil Health Care Weekly

XLV traded relatively flat last week, still holding support along its rising 21-DMA ($145.19). Support below this level is the rising 50-DMA
($142.30). We continue to recommend an equal-weight sector positioning given its RS line remains in a longer-term downtrend and
has yet to make short-term progress. With that said, we believe any sustained pullback in the market will result in relative
improvement in the sector.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq bounced off 21-DMA support (5,055/15,929) mid-week but staged a downside reversal on Friday. However, both indices remain near all-time highs and above 21-DMA support. The distribution day count increased to eight on the Nasdaq and remains at five on the S&P 500 with one day expiring on each index next week.

O’Neil Health Care Weekly

XLV declined 1% last week, but held 21-DMA ($144.64) support Friday. We continue to recommend an equal-weight sector
positioning as its RS line remains in a longer-term downtrend versus the broader market. Within the sector, we continue to
recommend an overweight positioning in Medical Technology and Biotech.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 finished strong and closed the week up 1%, while the Nasdaq gained 1.7%. Neither index has any remaining resistance as the S&P 500 continued further into all-time highs and the Nasdaq surpassed its 2021 peak of 16,212 for the first time. Indices have the first level of support at their 10-DMA (5,059/15,935). Below that, the 21-DMAs are the most major level of support (5,016/15,819). The distribution day count on each index stands at six, with one set to expire in the coming week.

O’Neil Health Care Weekly

XLV gained 1.5%, rallying for a fourth straight week as it trends along support at its 10-DMA ($145.41) and 21-DMA ($143.31). Despite
good absolute performance, we continue to recommend an equal-weight sector positioning as its RS line remains in a longer-term
downtrend versus the broader market.

O’Neil Health Care Weekly

XLV gained 1.1% last week continuing its move into new all-time highs. The 21-DMA ($142.42) has been acting as a solid level of
near-term support since November. The RS line has risen from lows, but has yet to make a higher high, warranting an equal-tounderweight sector positioning, which will likely change should the broader tape come under pressure.